CNSP
CNS Pharmaceuticals, Inc.NASDAQHealthcare$2.26+2.65%ClosedMarket Cap: $1.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.23
P/S
0.00
EV/EBITDA
0.35
DCF Value
$15.50
FCF Yield
-1037.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-164.6%
ROA
-183.8%
ROIC
-329.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | Infinity% | $-6.0M | $-6.0M | $-4.64 | — |
| FY 2025 | $0.00 | NaN% | $-16.0M | $-15.9M | $-35.75 | — |
| Q3 2025 | $0.00 | -Infinity% | $-3.3M | $-3.2M | $-5.76 | — |
| Q2 2025 | $0.00 | -Infinity% | $-2.4M | $-2.4M | $-6.42 | — |
| Q1 2025 | $0.00 | -Infinity% | $-4.3M | $-4.3M | $-18.93 | — |
| Q4 2024 | $0.00 | -Infinity% | $-3.2M | $-3.2M | $-26.96 | — |
| FY 2024 | $0.00 | -Infinity% | $-14.9M | $-14.9M | $-466.44 | — |
| Q3 2024 | $0.00 | -Infinity% | $-5.6M | $-5.6M | $-151.64 | — |
| Q2 2024 | $0.00 | -Infinity% | $-2.5M | $-2.5M | $-4,031.54 | — |
| Q1 2024 | $0.00 | -Infinity% | $-3.5M | $-3.5M | $-12,205.00 | — |
| Q4 2023 | $0.00 | -Infinity% | $-5.4M | $-5.4M | $-28,623.00 | — |
| FY 2023 | $0.00 | -Infinity% | $-18.9M | $-18.9M | $-150,114.00 | — |